Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell symbols : Nrix save search
Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors
Published: 2021-11-12 (Crawled : 13:00) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
treatment solid tumors potential therapy drug clearance t-cell
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
Published: 2021-10-27 (Crawled : 13:00) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 9.5%
H: 15.97%
C: 8.74%
phase 1 trial phase 1b t-cell
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit
Published: 2021-10-26 (Crawled : 22:00) - biospace.com/
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: 0.0%
phase 1 trial t-cell
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.